One Year Later, Where’s All the Adderall?
The U.S. is facing a mystery of missing Adderall—one for which nobody has an answer. Oct. 12 marked one year since the U.S. Food and Drug Administration’s formal announcement that pharmaceutical companies were unable to produce enough Adderall, one of the common amphetamine-based medications for attention-deficit/hyperactivity disorder (ADHD).
Other Articles in this Edition
Adults with ADHD are at increased risk for developing dementia
Craig Surman, MD: Sleep Drug Solriamfetol Can Effectively Treat ADHD
Overtalking may signal a mental health condition
Opinion: Moving forward with ADHD
One Year Later, Where’s All the Adderall?
Individuals with ADHD have higher risk of being involved in violence
Children With Non-US-Born Parents Less Likely to Receive ADHD Diagnosis
ADHD Diagnosis, Recommended Therapy More Likely in Older Children, Boys
Greater ADHD Symptoms Reported by Adults With Adverse Childhood Experiences
Barriers to ADHD Diagnosis in People with Epilepsy